Tilt Investment Management Holdings PBC Trims Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Tilt Investment Management Holdings PBC trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 23.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,052 shares of the pharmaceutical company’s stock after selling 325 shares during the quarter. Tilt Investment Management Holdings PBC’s holdings in Vertex Pharmaceuticals were worth $428,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. OFI Invest Asset Management purchased a new stake in Vertex Pharmaceuticals in the 3rd quarter worth approximately $25,000. Arlington Trust Co LLC raised its position in shares of Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 33 shares in the last quarter. Compass Wealth Management LLC bought a new stake in Vertex Pharmaceuticals during the fourth quarter valued at $29,000. Fortitude Family Office LLC bought a new position in Vertex Pharmaceuticals in the 4th quarter worth about $30,000. Finally, Baystate Wealth Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 25 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Oppenheimer restated an “outperform” rating and issued a $500.00 price objective on shares of Vertex Pharmaceuticals in a research report on Monday. JPMorgan Chase & Co. boosted their target price on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. HC Wainwright upped their price objective on shares of Vertex Pharmaceuticals from $457.00 to $462.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Royal Bank of Canada raised their price objective on Vertex Pharmaceuticals from $397.00 to $420.00 and gave the company a “sector perform” rating in a research note on Tuesday, February 6th. Finally, William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 6th. Three analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $429.45.

Insider Transactions at Vertex Pharmaceuticals

In related news, Chairman Jeffrey M. Leiden sold 2,656 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $419.51, for a total value of $1,114,218.56. Following the transaction, the chairman now directly owns 27,644 shares of the company’s stock, valued at approximately $11,596,934.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Chairman Jeffrey M. Leiden sold 2,656 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $419.51, for a total transaction of $1,114,218.56. Following the sale, the chairman now owns 27,644 shares of the company’s stock, valued at approximately $11,596,934.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,381 shares of company stock worth $5,203,249. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ VRTX traded up $2.46 on Thursday, reaching $395.56. 532,739 shares of the company’s stock traded hands, compared to its average volume of 1,239,377. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. The business’s 50 day simple moving average is $414.76 and its two-hundred day simple moving average is $396.76. Vertex Pharmaceuticals Incorporated has a 12 month low of $316.43 and a 12 month high of $448.40. The company has a market cap of $102.24 billion, a price-to-earnings ratio of 28.30, a price-to-earnings-growth ratio of 1.84 and a beta of 0.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The business had revenue of $2.52 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the previous year, the business earned $3.33 earnings per share. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.08 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.